News
SDGR
15.22
+1.20%
0.18
Schrödinger Shareholders Expand Equity Plan, Elect Directors
TipRanks · 17h ago
How Investors May Respond To Schrödinger (SDGR) Hosted Model Transition And Updated 2026 Targets
Simply Wall St · 17h ago
Schrodinger shareholders approve 3 million-share increase to 2022 equity incentive plan at annual meeting
PUBT · 18h ago
Weekly Report: what happened at SDGR last week (0615-0619)?
Weekly Report · 2d ago
Schrodinger grants 10,771 RSUs to seven new hires under inducement plan
PUBT · 6d ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Barchart · 6d ago
AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its Cash
Seeking Alpha · 06/17 10:33
Weekly Report: what happened at SDGR last week (0608-0612)?
Weekly Report · 06/15 09:46
Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR) and Climb Bio (CLYM)
TipRanks · 06/11 16:00
Schrödinger Finalizes Transition Terms for Former Commercial Chief
TipRanks · 06/08 21:38
Schrodinger confirms separation of Chief Commercial Officer Mannix Aklian
PUBT · 06/08 20:23
Weekly Report: what happened at SDGR last week (0601-0605)?
Weekly Report · 06/08 09:43
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool · 06/02 21:32
Does Schrödinger (SDGR) Changing Its CCO While Reaffirming Guidance Recast Its Commercial Playbook?
Simply Wall St · 06/02 05:16
Weekly Report: what happened at SDGR last week (0525-0529)?
Weekly Report · 06/01 09:46
Private Markets: Cognition AI raises $1B, Modal secures $355M
TipRanks · 05/28 17:37
Weekly Report: what happened at SDGR last week (0518-0522)?
Weekly Report · 05/25 09:48
Schrodinger grants inducement equity awards totaling 20,641 shares to new hires
PUBT · 05/22 12:30
SCHRÖDINGER REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 05/22 12:30
Analysts Are Bullish on These Healthcare Stocks: Personalis (PSNL), Eton Pharmaceuticals (ETON)
TipRanks · 05/21 16:50
More
Webull provides a variety of real-time SDGR stock news. You can receive the latest news about Schrodinger, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SDGR
Schrodinger, Inc. is a developer of a physics-based computational platform that enables discovery of molecules for drug development and materials applications. The Company's segments include Software and Drug Discovery. The Software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. It offers WaterMap, which characterizes the locations and energetics of water molecules occupying the binding site of, or solvating, a target protein. It also offers FEP+, which is a free energy calculation software which can be used to replace the central core of earlier known tight binding molecules to identify potent molecules unavailable in library collections. It can also be used to calculate absolute binding affinities.